Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib
Osimertinib is an oral epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used primarily in the treatment of metastatic non-small cell lung cancer. It is usually well tolerated with less than 5% of patients developing significant pulmonary toxicity from the medication, typically...
| Published in: | Case Reports in Oncological Medicine |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Online Access: | http://dx.doi.org/10.1155/2019/6185943 |